The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
True
Open accessAbstract
Currently the only tumour marker to have a well-defined and validated role in the management of ovarian cancer is CA125. Changes in the level of CA125 can be used as a reliable indication of response or progression according to various criteria, but it does not yet have a clear place in diagnosis or prognosis. Its value as part of a screening tool and during routine follow-up remain the subject of ongoing trials. Other markers remain experimental and do not have a well-defined contribution to make at present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Jacobs, I., Davies, A. P., Bridges, J., Stabile, I., Fay, T., Lower, A., Grudzinskas, J. G., & Oram, D. (1993) · BMJ · doi:10.1136/bmj.306.6884.1030 · Cited by 360
Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., & Lambert, H. E. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010602 · Cited by 283
Eisenhauer, E. A., Vermorken, J. B., & van Glabbeke, M. (1997) · Annals of Oncology · doi:10.1023/a:1008240421028 · Cited by 265
MULTIMODAL APPROACH TO SCREENING FOR OVARIAN CANCER
Jacobs, I., Bridges, J., Reynolds, C., Stabile, I., Kemsley, P., Grudzinskas, J., & Oram, D. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90351-0 · Cited by 241
Sier, C. F. M., Stephens, R. W., Bízik, J., Mariani, A., Bassan, M., Pedersen, N. M., Frigerio, L., Ferrari, A. G., Danø, K., Brünner, N., et al. (1998) · PubMed · Cited by 191
Tumor markers in the management of patients with ovarian cancer
Tuxen, M. K., Sölétormos, G., & Dombernowsky, P. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90002-0 · Cited by 160
Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy
van der Burg, M. E. L., Lammes, F. B., van Putten, W. L. J., & Stoter, G. (1988) · Gynecologic Oncology · doi:10.1016/0090-8258(88)90244-2 · Cited by 131
Bridgewater, J. A., Nelstrop, A. E., Rustin, G. J. S., Gore, M. E., McGuire, W. P., & Hoskins, W. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.501 · Cited by 119
The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer
van der Burg, M. E. L., Lammes, F. B., & Verweij, J. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057754 · Cited by 101
Nagele, F. (1995) · Obstetrics and Gynecology · doi:10.1016/0029-7844(95)00126-c · Cited by 100
van der Burg, M. E. L. (2001) · Current Treatment Options in Oncology · doi:10.1007/s11864-001-0053-1 · Cited by 86
Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn, N., Sjövall, K., Knapp, R. C., Hall, P., Scully, R. E., Bast, R. C., & Zurawski, V. R. (1992) · PubMed · Cited by 78
CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer
Sevelda, P., SCHEMPER, M., & Spona, J. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90668-6 · Cited by 65
Gadducci, A., Baicchi, U., Marrai, R., Ferdeghini, M., BIANCHI, R., & Facchini, V. (1996) · Gynecologic Oncology · doi:10.1006/gyno.1996.0025 · Cited by 59
Savings obtained by CA-125 measurements during therapy for ovarian carcinoma
Rustin, G. J. S., Nelstrop, A. E., Stilwell, J., & Lambert, H. E. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90390-n · Cited by 33
Cited by
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Welsh, J. B., Zarrinkar, P. P., Sapinoso, L. M., Kern, S. G., Behling, C. A., Monk, B. J., Lockhart, D. J., Burger, R. A., & Hampton, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1176 · Cited by 654
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Biosensors: the new wave in cancer diagnosis
Mousa, S. (2010) · Nanotechnology, Science and Applications · doi:10.2147/nsa.s13465 · Cited by 381
Metadata
- Venue
- British Journal of Cancer
- Published
- 2000
- Volume
- 82
- Issue
- 9
- Pages
- 1535-1538
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1594695427
- Cited by
- 276
- References
- 21
- FWCI
- 12.88
- Type
- journal article
- Language
- fr
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.